Suresh Alaparthy
Bristol-Myers Squibb (United States) · 22 works · 9,447 citations · h-index 14
Top works
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- An immune-active tumor microenvironment favors clinical response to ipilimumab
- Assessment of association between BRAF-V600E mutation status in melanomas and clinical response to ipilimumab
- First-line nivolumab (anti-PD-1; BMS-936558, ONO-4538) monotherapy in advanced NSCLC: Safety, efficacy, and correlation of outcomes with PD-L1 status.
- Potential immune biomarkers of gastrointestinal toxicities and efficacy in patients with advanced melanoma treated with ipilimumab with or without prophylactic budesonide
- Association of baseline and on-study tumor biopsy markers with clinical activity in patients (pts) with advanced melanoma treated with ipilimumab
- Randomized phase I pharmacokinetic study of ipilimumab with or without one of two different chemotherapy regimens in patients with untreated advanced melanoma.
- Immunological and Metabolic Effects of Prophylactic Insulin Therapy in the NOD-scid/scid Adoptive Transfer Model of IDDM
- Safety and response with nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus erlotinib in patients (pts) with epidermal growth factor receptor mutant (EGFR MT) advanced NSCLC.
- Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with platinum-based doublet chemotherapy (PT-DC) in advanced non-small cell lung cancer (NSCLC).
- A phase I study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus platinum-based doublet chemotherapy (PT-doublet) in chemotherapy-naive non-small cell lung cancer (NSCLC) patients (pts).
- Production of interleukin-1 and tumor necrosis factor by bone marrow-derived macrophages: effect of cisplatin and lipopolysaccharide
- Overexpression of manganese superoxide dismutase promotes survival in cell lines after doxorubicin treatment
- In vitro activation of murine bone marrow-derived macrophages with cisplatin and mitomycin-C
- Up-regulation of induction of lymphokine (IL-2)-activated killer (LAK) cell activity by FK-565 and cisplatin
- Quantitation of resistance to cytosine arabinoside by myeloid leukemic cells expressing bcl‐2
- In vitro activation of rGM‐CSF derived bone marrow macrophages by cisplatin and lipopolysaccharide
- Abstract 5513: An immune-active tumor microenvironment favors clinical response to ipilimumab
- Assessment of association between BRAF mutation status in melanoma tumors and response to ipilimumab.
- Effect of interferon-gamma, tumor necrosis factor, interleukin-1 and interleukin-6 on the modulation of anti-tumor responses of bone marrow derived macrophages